This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 1 EPO patent. Top assignees: Osong Medical Innovation Foundation, Kookmin University, Kookmin University Industry Academy Cooperation Foundation. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 15 
1 out of 170 
1 out of 19 Years Active: 2022-2026
Title: Innovations by Inventor Soo Han Lee in Antibody Technology
Introduction
Soo Han Lee, an accomplished inventor based in Seoul, South Korea, has made significant contributions to the field of antibody technology. With one patent to his name, his work focuses on enhancing the therapeutic potential of antibodies through innovative Fc variants.
Latest Patents
Soo Han Lee holds a patent for the invention titled "Antibody Fc Variants for Increased Blood Half-Life." This groundbreaking invention relates to a polypeptide that includes an Fc variant produced by substituting a portion of the amino acid sequence of the Fc domain of a human antibody with a different amino acid sequence. The Fc variant has promising applications in a variety of antibodies and Fc-fusion constructs. It is particularly noteworthy for its potential use in cancer treatment, where maximizing its in vivo half-life can improve therapeutic outcomes.
Career Highlights
Throughout his career, Soo Han Lee has been affiliated with prominent institutions including Kookmin University and the Osong Medical Innovation Foundation. His work primarily revolves around developing therapeutic reagents that target cancer cells, utilizing the inventive properties of antibodies and Fc-fusion constructs.
Collaborations
During his journey as an inventor, Soo Han Lee has collaborated with notable colleagues such as Sang Taek Jung and Sanghwan Ko. These partnerships have likely contributed to the development and refinement of his innovative concepts in antibody technology.
Conclusion
Soo Han Lee's innovative efforts in antibody Fc variants signify a meaningful advancement in medical research and therapeutic applications. His patent not only showcases his inventive spirit but also provides valuable insights into potential treatments for cancer, reflecting the broader implications of his work in the field of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile